DAXXIFY®
Glabellar Lines
Key Facts
About Revance
Revance Therapeutics is a commercial-stage biotech company with a mission to advance patient and physician experiences through innovative neuromodulator products. Its key achievement is the FDA approval and commercial launch of DAXXIFY® for glabellar lines, a novel, long-acting neuromodulator based on its proprietary peptide technology. The company's strategy is to disrupt the established neuromodulator market by leveraging DAXXIFY®'s clinical profile in aesthetics while developing a robust therapeutic pipeline in neurology. Its long-term goal is to build a leading, fully-integrated aesthetics and therapeutics company.
View full company profileAbout Revance
Revance Therapeutics is a commercial-stage biotech company with a mission to advance patient and physician experiences through innovative neuromodulator products. Its key achievement is the FDA approval and commercial launch of DAXXIFY® for glabellar lines, a novel, long-acting neuromodulator based on its proprietary peptide technology. The company's strategy is to disrupt the established neuromodulator market by leveraging DAXXIFY®'s clinical profile in aesthetics while developing a robust therapeutic pipeline in neurology. Its long-term goal is to build a leading, fully-integrated aesthetics and therapeutics company.
View full company profileAbout Revance
Revance Therapeutics is a commercial-stage biotech company with a mission to advance patient and physician experiences through innovative neuromodulator products. Its key achievement is the FDA approval and commercial launch of DAXXIFY® for glabellar lines, a novel, long-acting neuromodulator based on its proprietary peptide technology. The company's strategy is to disrupt the established neuromodulator market by leveraging DAXXIFY®'s clinical profile in aesthetics while developing a robust therapeutic pipeline in neurology. Its long-term goal is to build a leading, fully-integrated aesthetics and therapeutics company.
View full company profileAbout Revance
Revance Therapeutics is a commercial-stage biotech company with a mission to advance patient and physician experiences through innovative neuromodulator products. Its key achievement is the FDA approval and commercial launch of DAXXIFY® for glabellar lines, a novel, long-acting neuromodulator based on its proprietary peptide technology. The company's strategy is to disrupt the established neuromodulator market by leveraging DAXXIFY®'s clinical profile in aesthetics while developing a robust therapeutic pipeline in neurology. Its long-term goal is to build a leading, fully-integrated aesthetics and therapeutics company.
View full company profileAbout Revance
Revance Therapeutics is a commercial-stage biotech company with a mission to advance patient and physician experiences through innovative neuromodulator products. Its key achievement is the FDA approval and commercial launch of DAXXIFY® for glabellar lines, a novel, long-acting neuromodulator based on its proprietary peptide technology. The company's strategy is to disrupt the established neuromodulator market by leveraging DAXXIFY®'s clinical profile in aesthetics while developing a robust therapeutic pipeline in neurology. Its long-term goal is to build a leading, fully-integrated aesthetics and therapeutics company.
View full company profile